scholarly journals ME4 THE IMPACT OF MEDICARE PART D ON HEALTH CARE UTILIZATION AND HEALTH OF THE MEDICARE BENEFICIARIES

2010 ◽  
Vol 13 (3) ◽  
pp. A7
Author(s):  
FX Liu ◽  
GC Alexander ◽  
SY Crawford ◽  
AS Pickard ◽  
DR Hedeker ◽  
...  
2014 ◽  
Vol 17 (2) ◽  
pp. 196-204 ◽  
Author(s):  
Yu-Jung Wei ◽  
Francis B. Palumbo ◽  
Linda Simoni-Wastila ◽  
Lisa M. Shulman ◽  
Bruce Stuart ◽  
...  

2014 ◽  
Vol 7 (1) ◽  
pp. 64-69 ◽  
Author(s):  
Richard E. Nelson ◽  
Stephen L. Nelson ◽  
Benedikt Huttner ◽  
Adi Gundlapalli

Medical Care ◽  
2013 ◽  
Vol 51 (10) ◽  
pp. 888-893 ◽  
Author(s):  
Rui Li ◽  
Edward W. Gregg ◽  
Lawrence E. Barker ◽  
Ping Zhang ◽  
Fang Zhang ◽  
...  

Medicine ◽  
2019 ◽  
Vol 98 (12) ◽  
pp. e14871 ◽  
Author(s):  
Kiran Raj Pandey ◽  
Fan Yang ◽  
Kathleen A. Cagney ◽  
Fabrice Smieliauskas ◽  
David O. Meltzer ◽  
...  

2015 ◽  
Vol 33 (29_suppl) ◽  
pp. 155-155
Author(s):  
Elizabeth Ann Kvale ◽  
Gabrielle Rocque ◽  
Kerri S. Bevis ◽  
Aras Acemgil ◽  
Richard A. Taylor ◽  
...  

155 Background: Healthcare utilization and costs escalate near diagnosis and in the final months of life. There is a national trend toward aggressive care at end of life (EOL). We examined patterns in utilization and cost across the trajectory of care and during the last two weeks of life during implementation of a lay navigation intervention. Methods: Claims data were obtained for Medicare beneficiaries ≥ 65 years old with cancer in the UAB Health System Cancer Community Network (UAB CCN). For 10 quarters from January 2012 -June 2014, we examined healthcare utilization for the population at large, navigated patients, and decedents. All analyses included ER visits, hospitalizations, and ICU admissions and use of chemotherapy in the last 2 weeks of life, and hospice utilization (admission or less than 3 days of hospice) in the quarter of death for decedents. Descriptive analyses and linear regression were used to test trends over time; general linear models evaluated changes in health care utilization and cost. Results: Across the population reduction of 13.4% to 11% for hospitalization (18% decrease, p < 0.01), 8.0% to 7.1% for ER visits (12% decrease, p < 0.01), 2.9% to 2.5% for ICU admissions (14% decrease, p = 0.04) and an increase of 3.9% to 4.3% for hospice (9.2% increase p = 0.37) were found. Among 5,861 decedents, in the last 2 weeks of life, there were decreases in ICU admissions (14.6% decrease, p = 0.11), from 39.2% to 32.0%, ER visits (18.4% decrease, p = 0.03), and chemotherapy, from 4.7% to 3.5% (25.5% decrease, p = 0.11).Over the 10 quarters, hospice enrollment increased from 70.7% to 77.4% (9.48% increase; p = 0.06), and the proportion of patients on hospice for less than 3 days changed from 7.8% to 7.5% (3.85% decrease, p = 0.30). Costs decreased about $158 per quarter per beneficiary. A significant pre-post decrease of $952 per beneficiary (p < 0.01) led to an estimated reduction in Medicare costs of $18,406,920 for the 19,335 beneficiaries in the UAB CCN for the five quarters post-implementation. Conclusions: We observed decreased healthcare utilization and cost and trends toward decreased aggressive care at EOL in the UAB CCN. Further work is needed to determine the impact of navigation on utilization trends.


2016 ◽  
Vol 5 (4) ◽  
pp. 383-392
Author(s):  
Z Kevin Lu ◽  
Minghui Li ◽  
Karen McGee ◽  
Cynthia M Phillips ◽  
Jing Yuan ◽  
...  

2017 ◽  
Vol 35 (22) ◽  
pp. 2482-2489 ◽  
Author(s):  
Ya-Chen Tina Shih ◽  
Ying Xu ◽  
Lei Liu ◽  
Fabrice Smieliauskas

Purpose The high cost of oncology drugs threatens the affordability of cancer care. Previous research identified drivers of price growth of targeted oral anticancer medications (TOAMs) in private insurance plans and projected the impact of closing the coverage gap in Medicare Part D in 2020. This study examined trends in TOAM prices and patient out-of-pocket (OOP) payments in Medicare Part D and estimated the actual effects on patient OOP payments of partial filling of the coverage gap by 2012. Methods Using SEER linked to Medicare Part D, 2007 to 2012, we identified patients who take TOAMs via National Drug Codes in Part D claims. We calculated total drug costs (prices) and OOP payments per patient per month and compared their rates of inflation with general health care prices. Results The study cohort included 42,111 patients who received TOAMs between 2007 and 2012. Although the general prescription drug consumer price index grew at 3% per year over 2007 to 2012, mean TOAM prices increased by nearly 12% per year, reaching $7,719 per patient per month in 2012. Prices increased over time for newly and previously launched TOAMs. Mean patient OOP payments dropped by 4% per year over the study period, with a 40% drop among patients with a high financial burden in 2011, when the coverage gap began to close. Conclusion Rising TOAM prices threaten the financial relief patients have begun to experience under closure of the coverage gap in Medicare Part D. Policymakers should explore methods of harnessing the surge of novel TOAMs to increase price competition for Medicare beneficiaries.


Sign in / Sign up

Export Citation Format

Share Document